JP6614724B2 - シクロベンザプリン塩酸塩の共融製剤 - Google Patents

シクロベンザプリン塩酸塩の共融製剤 Download PDF

Info

Publication number
JP6614724B2
JP6614724B2 JP2017535609A JP2017535609A JP6614724B2 JP 6614724 B2 JP6614724 B2 JP 6614724B2 JP 2017535609 A JP2017535609 A JP 2017535609A JP 2017535609 A JP2017535609 A JP 2017535609A JP 6614724 B2 JP6614724 B2 JP 6614724B2
Authority
JP
Japan
Prior art keywords
mannitol
eutectic
cyclobenzaprine hcl
pharmaceutical composition
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017535609A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017532374A5 (cg-RX-API-DMAC7.html
JP2017532374A (ja
Inventor
セス レーデルマン，
マリーノ ネブローニ，
Original Assignee
トニックス ファーマ ホールディングス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トニックス ファーマ ホールディングス リミテッド filed Critical トニックス ファーマ ホールディングス リミテッド
Publication of JP2017532374A publication Critical patent/JP2017532374A/ja
Publication of JP2017532374A5 publication Critical patent/JP2017532374A5/ja
Application granted granted Critical
Publication of JP6614724B2 publication Critical patent/JP6614724B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2017535609A 2014-09-18 2015-09-18 シクロベンザプリン塩酸塩の共融製剤 Active JP6614724B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462052238P 2014-09-18 2014-09-18
US62/052,238 2014-09-18
PCT/US2015/051068 WO2016044796A1 (en) 2014-09-18 2015-09-18 Eutectic formulations of cyclobenzaprine hydrochloride

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018173466A Division JP6717902B6 (ja) 2014-09-18 2018-09-18 シクロベンザプリン塩酸塩の共融製剤

Publications (3)

Publication Number Publication Date
JP2017532374A JP2017532374A (ja) 2017-11-02
JP2017532374A5 JP2017532374A5 (cg-RX-API-DMAC7.html) 2018-11-01
JP6614724B2 true JP6614724B2 (ja) 2019-12-04

Family

ID=55533932

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2017535609A Active JP6614724B2 (ja) 2014-09-18 2015-09-18 シクロベンザプリン塩酸塩の共融製剤
JP2018173466A Active JP6717902B6 (ja) 2014-09-18 2018-09-18 シクロベンザプリン塩酸塩の共融製剤
JP2019236602A Withdrawn JP2020059757A (ja) 2014-09-18 2019-12-26 シクロベンザプリン塩酸塩の共融製剤
JP2021169539A Withdrawn JP2022001605A (ja) 2014-09-18 2021-10-15 シクロベンザプリン塩酸塩の共融製剤
JP2023116057A Withdrawn JP2023126486A (ja) 2014-09-18 2023-07-14 シクロベンザプリン塩酸塩の共融製剤
JP2025076812A Pending JP2025107355A (ja) 2014-09-18 2025-05-02 シクロベンザプリン塩酸塩の共融製剤

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2018173466A Active JP6717902B6 (ja) 2014-09-18 2018-09-18 シクロベンザプリン塩酸塩の共融製剤
JP2019236602A Withdrawn JP2020059757A (ja) 2014-09-18 2019-12-26 シクロベンザプリン塩酸塩の共融製剤
JP2021169539A Withdrawn JP2022001605A (ja) 2014-09-18 2021-10-15 シクロベンザプリン塩酸塩の共融製剤
JP2023116057A Withdrawn JP2023126486A (ja) 2014-09-18 2023-07-14 シクロベンザプリン塩酸塩の共融製剤
JP2025076812A Pending JP2025107355A (ja) 2014-09-18 2025-05-02 シクロベンザプリン塩酸塩の共融製剤

Country Status (12)

Country Link
US (2) US10357465B2 (cg-RX-API-DMAC7.html)
EP (1) EP3193854A4 (cg-RX-API-DMAC7.html)
JP (6) JP6614724B2 (cg-RX-API-DMAC7.html)
CN (2) CN112618494B (cg-RX-API-DMAC7.html)
AU (2) AU2015317336B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017005231A2 (cg-RX-API-DMAC7.html)
IL (2) IL251218B (cg-RX-API-DMAC7.html)
MX (1) MX387402B (cg-RX-API-DMAC7.html)
MY (1) MY186047A (cg-RX-API-DMAC7.html)
SG (2) SG11201701995PA (cg-RX-API-DMAC7.html)
WO (1) WO2016044796A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201701637B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2501234T3 (en) 2009-11-20 2017-12-04 Tonix Pharma Holdings Ltd METHODS AND COMPOSITIONS FOR TREATING SYMPTOMS CONNECTED WITH POSTTRAUMATIC LOAD RESPONSE USING CYCLOBENZAPRINE
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
CN110152005B (zh) 2013-03-15 2023-08-04 通尼克斯制药控股有限公司 环苯扎林盐酸盐和阿米替林盐酸盐的低共熔混合物配制剂
CN112618494B (zh) 2014-09-18 2023-06-30 通尼克斯制药控股有限公司 环苯扎林盐酸盐的低共熔混合物配制剂
CA3083341C (en) 2017-12-11 2024-05-28 Tonix Pharma Holdings Limited Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
BR112021003107A2 (pt) * 2018-08-20 2021-05-11 Tonix Pharma Holdings Limited métodos de tratamento de transtorno de estresse agudo e transtorno de estresse pós-traumático
NL2023661B1 (en) * 2019-08-19 2021-04-21 Seranovo Holding B V Pharmaceutical Eutectic Salt Formulation
JP7780447B2 (ja) * 2020-04-08 2025-12-04 トニックス ファーマシューティカルズ ホールディング コーポレイション 性機能障害のシクロベンザプリン処置
WO2022109218A1 (en) * 2020-11-20 2022-05-27 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for alcohol use disorder
US20240024256A1 (en) * 2020-12-07 2024-01-25 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for fibromyalgia
US20240415789A1 (en) 2021-10-06 2024-12-19 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine for treatment or prevention of sexual dysfunction associated with mental health conditions in female patients
AU2023286504A1 (en) 2022-06-21 2025-01-16 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for post-acute sequelae of (sars)-cov-2 infection (pasc)
WO2025160302A1 (en) 2024-01-25 2025-07-31 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for acute stress reaction or acute stress disorder

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968507A (en) 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
SG47101A1 (en) 1992-07-31 1998-03-20 Us Bioscience Crystalline amifostine compositions and methods for the preparation and use of same
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US5498421A (en) 1993-02-22 1996-03-12 Vivorx Pharmaceuticals, Inc. Composition useful for in vivo delivery of biologics and methods employing same
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US20030077227A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
WO1999018937A1 (en) * 1997-10-16 1999-04-22 Merck & Co., Inc. New cyclobenzaprine composition
DE69904465T2 (de) 1998-05-14 2003-10-02 Alza Corp., Mountain View Therapie von depressionen
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
EP1202721A1 (en) 1999-08-13 2002-05-08 Vela Pharmaceuticals Inc. Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof
CA2380432A1 (en) 1999-08-13 2001-02-22 Iredell W. Iglehart, Iii Uses compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
WO2001089476A1 (en) 2000-05-19 2001-11-29 Npd Llc Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
NZ532583A (en) 2001-11-05 2006-12-22 Krele Pharmaceuticals Compositions and methods for increasing compliance using aldehyde dehydrogenase inhibitors ( ALDH ) such as disulfiram and monoamine oxidase B inhibitors ( MAOB ) such as selegiline
US7700561B2 (en) 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
US7105486B2 (en) 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
US7659253B2 (en) 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
CA2503381A1 (en) 2002-10-25 2004-05-13 Collegium Pharmaceutical, Inc. Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof
JP2006524632A (ja) 2002-12-09 2006-11-02 アメリカン バイオサイエンス、インコーポレイテッド 組成物及び薬物送達方法
SI1644019T2 (en) 2003-05-29 2018-04-30 Shire Llc AMPHETAMINE COMPOUNDS COMPOUNDS TO ABUSE
WO2005042501A1 (en) 2003-11-03 2005-05-12 Warner-Lambert Company Llc Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
US20050143350A1 (en) 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
JP2007516259A (ja) 2003-12-09 2007-06-21 メッドクリスタルフォームズ、エルエルシー 活性剤との混合相共結晶の調製方法
KR20130116378A (ko) 2004-02-17 2013-10-23 트랜스셉트 파마슈티칼스, 인코포레이티드 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의 사용 방법
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
US20070196364A1 (en) * 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
US7532935B2 (en) 2005-07-29 2009-05-12 Cyberonics, Inc. Selective neurostimulation for treating mood disorders
US7994220B2 (en) 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20080146672A1 (en) 2006-12-08 2008-06-19 Denton Marcia Marye Topical Eutectic Anesthetic Composition for Oral or Dermal Tissue
JP2010530874A (ja) 2007-06-22 2010-09-16 メルク・シャープ・エンド・ドーム・コーポレイション ６，５−ピロロピペリジンタキキニン受容体アンタゴニスト
CN101951912A (zh) 2007-07-23 2011-01-19 辛诺西亚治疗公司 创伤后应激障碍的治疗
US20090060983A1 (en) 2007-08-30 2009-03-05 Bunick Frank J Method And Composition For Making An Orally Disintegrating Dosage Form
PL2200588T3 (pl) 2007-09-25 2019-09-30 Solubest Ltd. Kompozycje zawierające lipofilowe związki aktywne i sposób ich wytwarzania
US20100247649A1 (en) 2007-10-30 2010-09-30 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
US20090148532A1 (en) 2007-12-06 2009-06-11 Venkatesh Gopi M Preparation of controlled release skeletal muscle relaxant dosage forms
JP5714910B2 (ja) 2008-01-09 2015-05-07 チャールストン ラボラトリーズ，インコーポレイテッド 薬学的組成物
US9314469B2 (en) 2008-05-05 2016-04-19 Tonix Pharma Holdings Limited Method for treating neurocognitive dysfunction
JP5380909B2 (ja) 2008-05-30 2014-01-08 株式会社ブリヂストン 金型及び樹脂発泡成形品の成形方法
US20100266682A1 (en) 2008-12-10 2010-10-21 Nipun Davar Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same
US20100247586A1 (en) 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
EP2233134A1 (en) 2009-03-27 2010-09-29 McNeil AB Multi-portion intra-oral dosage form with organoleptic properties
US8871263B2 (en) 2009-09-24 2014-10-28 Mcneil-Ppc, Inc. Manufacture of tablet in a die utilizing radiofrequency energy and meltable binder
DK2501234T3 (en) 2009-11-20 2017-12-04 Tonix Pharma Holdings Ltd METHODS AND COMPOSITIONS FOR TREATING SYMPTOMS CONNECTED WITH POSTTRAUMATIC LOAD RESPONSE USING CYCLOBENZAPRINE
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
PT2611440T (pt) 2010-09-01 2017-04-26 Tonix Pharmaceuticals Inc Tratamento para a dependência de cocaína
US11998516B2 (en) * 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
HUE060175T2 (hu) * 2012-06-15 2023-02-28 Tonix Pharma Holdings Ltd Transzmukózális felszívódásra szolgáló készítmények és módszerek
CN110152005B (zh) * 2013-03-15 2023-08-04 通尼克斯制药控股有限公司 环苯扎林盐酸盐和阿米替林盐酸盐的低共熔混合物配制剂
CN112618494B (zh) * 2014-09-18 2023-06-30 通尼克斯制药控股有限公司 环苯扎林盐酸盐的低共熔混合物配制剂

Also Published As

Publication number Publication date
IL277814B (en) 2021-12-01
CA2961822A1 (en) 2016-03-24
NZ730379A (en) 2023-10-27
JP6717902B6 (ja) 2020-08-05
BR112017005231A2 (pt) 2018-03-13
MX2017003644A (es) 2017-10-31
NZ768064A (en) 2023-10-27
AU2015317336B2 (en) 2021-01-21
JP2017532374A (ja) 2017-11-02
SG11201701995PA (en) 2017-04-27
WO2016044796A1 (en) 2016-03-24
US10357465B2 (en) 2019-07-23
JP2023126486A (ja) 2023-09-07
CN107072968A (zh) 2017-08-18
JP2018193409A (ja) 2018-12-06
US11026898B2 (en) 2021-06-08
AU2020289838B2 (en) 2022-11-24
EP3193854A4 (en) 2018-05-02
SG10201902203VA (en) 2019-04-29
MX387402B (es) 2025-03-18
CN107072968B (zh) 2021-01-12
EP3193854A1 (en) 2017-07-26
JP2022001605A (ja) 2022-01-06
JP6717902B2 (ja) 2020-07-08
MY186047A (en) 2021-06-17
IL251218A0 (en) 2017-05-29
AU2015317336A1 (en) 2017-04-13
AU2020289838A1 (en) 2021-01-28
JP2025107355A (ja) 2025-07-17
ZA201701637B (en) 2020-11-25
JP2020059757A (ja) 2020-04-16
CN112618494A (zh) 2021-04-09
IL277814A (en) 2020-11-30
IL251218B (en) 2020-10-29
CN112618494B (zh) 2023-06-30
US20190336458A1 (en) 2019-11-07
US20170281568A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
JP6614724B2 (ja) シクロベンザプリン塩酸塩の共融製剤
JP6310542B2 (ja) シクロベンザプリン塩酸塩およびアミトリプチリン塩酸塩の共融製剤
HK40047283B (en) Eutectic formulations of cyclobenzaprine hydrochloride
CA2961822C (en) Eutectic formulations of cyclobenzaprine hydrochloride
HK40047283A (en) Eutectic formulations of cyclobenzaprine hydrochloride
NZ768064B2 (en) Eutectic formulations of cyclobenzaprine hydrochloride
NZ730379B2 (en) Eutectic formulations of cyclobenzaprine hydrochloride
HK40013124B (zh) 环苯扎林盐酸盐和阿米替林盐酸盐的低共熔混合物配制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180918

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190927

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191031

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191101

R150 Certificate of patent or registration of utility model

Ref document number: 6614724

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250